All > Paid Studies Dallas > Rectal Cancer

CTX-009 Treatment for Metastatic Colorectal Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Metastatic Colorectal Cancer+2 MoreCTX-009 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer. A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.

Eligible Conditions
  • Metastatic Colorectal Cancer
  • Colon Cancer
  • Colorectal Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Colorectal Cancer Peptide Vaccine PolyPEPI1018
1
CTX-471
1
ELU001

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: From C1D1 to death from any cause, average of 9 months

Month 7
Safety Profile of CTX-009
Month 9
Overall Survival
Month 6
Progression Free Survival
Month 6
Disease Control Rate
Exposure Response by Pharmacokinetic (PK) Sampling
Month 6
Overall Response Rate
Month 6
Duration of Response
Month 6
Quality of Life Changes

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Colorectal Cancer Peptide Vaccine PolyPEPI1018
1
CTX-471
1
ELU001

Trial Design

1 Treatment Group

CTX-009 Treatment
1 of 1

Experimental Treatment

84 Total Participants · 1 Treatment Group

Primary Treatment: CTX-009 Treatment · No Placebo Group · Phase 2

CTX-009 Treatment
Drug
Experimental Group · 1 Intervention: CTX-009 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from c1d1 to death from any cause, average of 9 months

Who is running the clinical trial?

Compass TherapeuticsLead Sponsor
3 Previous Clinical Trials
399 Total Patients Enrolled
Thomas J Schuetz, MD, PhDStudy DirectorCompass Therapeutics

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a histologically or cytologically confirmed metastatic or recurrent colorectal cancer.
You have a primary tumor that has been resected > 3 months prior to starting therapy with CTX-009.
You have at least one lesion measurable as defined by RECIST v1.1.
You have a performance status of 0 or 1.
You have a predicted life expectancy of at least 12 weeks.
You have an estimated creatinine clearance of 30 mL/min or greater.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top